{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:27:40Z","timestamp":1786494460874,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008375","name":"University of Basel","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"abstract":"Abstract<\/jats:title>\n \n Purpose<\/jats:title>\n \n Metastatic pheochromocytomas and paragangliomas (mPPGLs) are rare neuroendocrine tumours with limited therapeutic options. Peptide receptor radionuclide therapy (PRRT) using somatostatin receptor (SSTR) antagonists (e.g. [\n 177<\/jats:sup>\n Lu]Lu-DOTA-JR11) may achieve higher tumour and organ absorbed doses compared with standard SSTR agonist therapy (e.g. [\n 177<\/jats:sup>\n Lu]Lu-DOTA-TOC). This study aimed to perform an intra-patient comparison of tumour and organ dosimetry between [\n 177<\/jats:sup>\n Lu]Lu-DOTA-TOC and [\n 177<\/jats:sup>\n Lu]Lu-DOTA-JR11 in patients with mPPGLs refractory to conventional therapies. Secondary endpoints included safety and exploratory clinical efficacy of [\n 177<\/jats:sup>\n Lu]Lu-DOTA-JR11.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n In this retrospective pilot study, 6 patients with mPPGLs received 1\u20132 cycles of [\n 177<\/jats:sup>\n Lu]Lu-DOTA-TOC (~\u20097.4 GBq\/cycle), followed by 1\u20132 cycles of [\n 177<\/jats:sup>\n Lu]Lu-DOTA-JR11 (2 GBq\/m\n 2<\/jats:sup>\n \u00d7 body surface area) at an interval of 10\u201312 weeks. Endpoints included estimation of tumour and organ absorbed doses, assessment of safety according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 and symptoms, and evaluation of progression-free survival (PFS) before and after [\n 177<\/jats:sup>\n Lu]Lu-DOTA-JR11 therapy.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Intra-patient comparison showed that the median tumour absorbed dose per cycle was 1.3-fold higher (range 0.9\u20133.5) with [\n 177<\/jats:sup>\n Lu]Lu-DOTA-JR11 than with [\n 177<\/jats:sup>\n Lu]Lu-DOTA-TOC. This was associated with longer PFS after [\n 177<\/jats:sup>\n Lu]Lu-DOTA-JR11 (12.5 months; range 6 \u2013 >20) versus PFS before inclusion (3.5 months; range 1\u20139). The most severe adverse event was grade 3 lymphopenia in one patient. No thrombocytopenia, neutropenia, creatinine elevation or alanine aminotransferase elevation was observed.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n [\n 177<\/jats:sup>\n Lu]Lu-DOTA-JR11 resulted in higher tumour absorbed doses than [\n 177<\/jats:sup>\n Lu]Lu-DOTA-TOC and was associated with longer post-treatment PFS than PFS before inclusion in this small cohort. Treatment was well tolerated, supporting further prospective evaluation in patients with mPPGLs.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1007\/s00259-026-08122-8","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T23:38:26Z","timestamp":1786491506000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Radiolabelled somatostatin receptor antagonist versus agonist for peptide receptor radionuclide therapy in patients with metastatic pheochromocytoma or paraganglioma: a retrospective pilot study"],"prefix":"10.1007","author":[{"given":"Felix","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia-Maria","family":"Lider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"McDougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Eigler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrafee","family":"Mushaweh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Bauman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melpomeni","family":"Fani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Christ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8135-5350","authenticated-orcid":false,"given":"Damian","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"issue":"8","key":"8122_CR1","doi-asserted-by":"publisher","first-page":"e13306","DOI":"10.1111\/jne.13306","volume":"35","author":"F Panzuto","year":"2023","unstructured":"Panzuto F, Ramage J, Pritchard DM, et al. European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for gastroduodenal neuroendocrine tumours (NETs) G1\u2013G3. J Neuroendocrinol. 2023;35(8):e13306. https:\/\/doi.org\/10.1111\/jne.13306.","journal-title":"J Neuroendocrinol"},{"issue":"Suppl 2","key":"8122_CR2","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1038\/modpathol.2010.166","volume":"24","author":"J Rosai","year":"2011","unstructured":"Rosai J. The origin of neuroendocrine tumors and the neural crest saga. Mod Pathol. 2011;24(Suppl 2):S53\u20137. https:\/\/doi.org\/10.1038\/modpathol.2010.166.","journal-title":"Mod Pathol"},{"key":"8122_CR3","doi-asserted-by":"publisher","first-page":"101116","DOI":"10.1016\/j.currproblcancer.2024.101116","volume":"51","author":"V Sukrithan","year":"2024","unstructured":"Sukrithan V, Perez K, Pandit-Taskar N, Jimenez C. Management of metastatic pheochromocytomas and paragangliomas: when and what. Curr Probl Cancer. 2024;51:101116. https:\/\/doi.org\/10.1016\/j.currproblcancer.2024.101116.","journal-title":"Curr Probl Cancer"},{"issue":"1091","key":"8122_CR4","doi-asserted-by":"publisher","first-page":"20180440","DOI":"10.1259\/bjr.20180440","volume":"91","author":"JH Turner","year":"2018","unstructured":"Turner JH. An introduction to the clinical practice of theranostics in oncology. Br J Radiol. 2018;91(1091):20180440. https:\/\/doi.org\/10.1259\/bjr.20180440.","journal-title":"Br J Radiol"},{"key":"8122_CR5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.humpath.2018.11.020","volume":"86","author":"H Leijon","year":"2019","unstructured":"Leijon H, Remes S, Hagstr\u00f6m J, et al. Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas. Hum Pathol. 2019;86:66\u201375. https:\/\/doi.org\/10.1016\/j.humpath.2018.11.020.","journal-title":"Hum Pathol"},{"issue":"11","key":"8122_CR6","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1210\/clinem\/dgac471","volume":"107","author":"K Wang","year":"2022","unstructured":"Wang K, Crona J, Beuschlein F, Grossman AB, Pacak K, N\u00f6lting S. Targeted therapies in pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2022;107(11):2963\u201372. https:\/\/doi.org\/10.1210\/clinem\/dgac471.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"8122_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1530\/EJE-18-0901","volume":"181","author":"WT Zandee","year":"2019","unstructured":"Zandee WT, Feelders RA, Smit Duijzentkunst DA, et al. Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE. Eur J Endocrinol. 2019;181(1):45\u201353. https:\/\/doi.org\/10.1530\/EJE-18-0901.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"8122_CR8","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s00259-016-3486-2","volume":"44","author":"P Brunner","year":"2017","unstructured":"Brunner P, J\u00f6rg AC, Glatz K, et al. The prognostic and predictive value of sstr2-immunohistochemistry and sstr2-targeted imaging in neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2017;44(3):468\u201375. https:\/\/doi.org\/10.1007\/s00259-016-3486-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"8122_CR9","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1093\/ejendo\/lvad146","volume":"189","author":"A Fischer","year":"2023","unstructured":"Fischer A, Kloos S, Remde H, et al. Responses to systemic therapy in metastatic pheochromocytoma\/paraganglioma: a retrospective multicenter cohort study. Eur J Endocrinol. 2023;189(5):546\u201365. https:\/\/doi.org\/10.1093\/ejendo\/lvad146.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"8122_CR10","first-page":"334","volume":"52","author":"F Forrer","year":"2008","unstructured":"Forrer F, Riedweg I, Maecke HR, Mueller-Brand J. Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging. 2008;52(4):334\u201340.","journal-title":"Q J Nucl Med Mol Imaging"},{"issue":"17","key":"8122_CR11","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","volume":"29","author":"A Imhof","year":"2011","unstructured":"Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29(17):2416\u201323. https:\/\/doi.org\/10.1200\/JCO.2010.33.7873.","journal-title":"J Clin Oncol"},{"issue":"44","key":"8122_CR12","doi-asserted-by":"publisher","first-page":"16436","DOI":"10.1073\/pnas.0607761103","volume":"103","author":"M Ginj","year":"2006","unstructured":"Ginj M, Zhang H, Waser B, et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci U S A. 2006;103(44):16436\u201341. https:\/\/doi.org\/10.1073\/pnas.0607761103.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"8122_CR13","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.2967\/jnumed.114.138834","volume":"55","author":"D Wild","year":"2014","unstructured":"Wild D, Fani M, Fischer R, et al. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study. J Nucl Med. 2014;55(8):1248\u201352. https:\/\/doi.org\/10.2967\/jnumed.114.138834.","journal-title":"J Nucl Med"},{"issue":"Suppl 2","key":"8122_CR14","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.2967\/jnumed.116.186783","volume":"58","author":"M Fani","year":"2017","unstructured":"Fani M, Nicolas GP, Wild D. Somatostatin receptor antagonists for imaging and therapy. J Nucl Med. 2017;58(Suppl 2):S61\u20136. https:\/\/doi.org\/10.2967\/jnumed.116.186783.","journal-title":"J Nucl Med"},{"issue":"2","key":"8122_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, et al. NETTER-1 Trial Investigators. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"issue":"4","key":"8122_CR16","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2967\/jnumed.123.266817","volume":"65","author":"C Eigler","year":"2024","unstructured":"Eigler C, McDougall L, Bauman A, et al. Radiolabeled somatostatin receptor antagonist versus agonist for peptide receptor radionuclide therapy in patients with therapy-resistant meningioma: PROMENADE Phase 0 study. J Nucl Med. 2024;65(4):573\u20139. https:\/\/doi.org\/10.2967\/jnumed.123.266817.","journal-title":"J Nucl Med"},{"key":"8122_CR17","doi-asserted-by":"publisher","first-page":"1141648","DOI":"10.3389\/fonc.2023.1141648","volume":"13","author":"D Su","year":"2023","unstructured":"Su D, Yang H, Qiu C, Chen Y. Peptide receptor radionuclide therapy in advanced Pheochromocytomas and Paragangliomas: a systematic review and meta-analysis. Front Oncol. 2023;13:1141648. https:\/\/doi.org\/10.3389\/fonc.2023.1141648.","journal-title":"Front Oncol"},{"issue":"28","key":"8122_CR18","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1200\/JCO-25-00791","volume":"43","author":"FI Lin","year":"2025","unstructured":"Lin FI, Del Rivero J, Carrasquillo JA, et al. Phase II Study of 177Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and Biomarkers. J Clin Oncol. 2025;43(28):3102\u201312. https:\/\/doi.org\/10.1200\/JCO-25-00791.","journal-title":"J Clin Oncol"},{"issue":"23","key":"8122_CR19","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1158\/1078-0432.CCR-19-1026","volume":"25","author":"D Reidy-Lagunes","year":"2019","unstructured":"Reidy-Lagunes D, Pandit-Taskar N, O\u2019Donoghue JA, et al. Phase I trial of well-differentiated neuroendocrine tumors (NETs) with radiolabeled somatostatin antagonist 177Lu-satoreotide tetraxetan. Clin Cancer Res. 2019;25(23):6939\u201347. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1026.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"8122_CR20","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00259-023-06383-1","volume":"51","author":"D Wild","year":"2024","unstructured":"Wild D, Gr\u00f8nb\u00e6k H, Navalkissoor S, et al. A phase I\/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2024;51(1):183\u201395. https:\/\/doi.org\/10.1007\/s00259-023-06383-1.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08122-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08122-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08122-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T23:38:28Z","timestamp":1786491508000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08122-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":20,"alternative-id":["8122"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08122-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"assertion":[{"value":"30 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Ethics Committee of Northwest and Central Switzerland approved the data collection and evaluation (2024\u201302047). The study was performed in accordance with the principles of the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that human research participants provided informed consent for publication of their data in this article.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All patients provided signed, written informed consent.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest relevant to this article.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}